Search Results

Vultr, the world’s largest, privately-held cloud computing platform, today announced that Athos Therapeutics, Inc. (“Athos”), a clinical-stage biotechnology company, has chosen Vultr Cloud GPU to run its AI model training, tuning, and inference.

Athos Therapeutics, Inc. (“Athos”) announced today that it has been granted a CTN acknowledgement from the Australian Therapeutic Goods Administration and has received Human Research Ethics Committee (“HREC”) approval to commence a Phase I clinical trial of ATH-063 in Australia.

Athos Therapeutics, Inc. (“Athos”) is a late-stage preclinical biotech company using Artificial Intelligence (AI) to develop small molecule therapeutics for immune-mediated diseases and cancer.

Athos Therapeutics, Inc. (“Athos”), a late-stage preclinical biotech company using artificial intelligence to develop small molecule therapeutics for immune-mediated diseases and cancer, announced today a comprehensive Master Research Agreement for a collaborative project on Inflammatory Bowel Disease (IBD) with Lahey Hospital & Medical Center (“Lahey”).

ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, announced an equity investment of €188 million led by Temasek with participation from funds managed by BlackRock, Qatar Investment Authority, ATHOS and Carbyne.

Athos Therapeutics, Inc. announced today the completion of an oversubscribed $15MM Series A financing.

Athos Therapeutics, Inc. (the “Company”), a late-stage preclinical biotech company using artificial intelligence to develop small molecule therapeutics for immune-mediated diseases and cancer, announced today that Yiannis Monovoukas , PhD, MBA, and Monte Stettin were appointed as advisors and observers to the Board of Directors.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Athos Therapeutics, Inc., a late-stage preclinical biotech company using artificial intelligence to develop small molecule therapeutics for immune-mediated diseases and cancer, announced that Abraham Verghese, MD, MACP has been named to the Company’s Board of Directors.